Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00784836 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT00784836 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 3 participants.
The verdict
NCT00784836, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
The primary objective of the study was to evaluate the immunogenicity of Avonex® (interferon beta-1a) 30 mcg when administered subcutaneously (SC) to interferon-naïve participants with relapsing multiple sclerosis. The secondary objective of this study was to evaluate the safety and tolerability of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing MS.
Interventions
- DRUG BG9418 (interferon beta 1-a)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00784836
The ClinicalTrials.gov registry entry for NCT00784836 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BG9418 (interferon beta 1-a) is the first listed.
NCT00784836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00784836 about?
NCT00784836 is a clinical study titled "Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients". The primary objective of the study was to evaluate the immunogenicity of Avonex® (interferon beta-1a) 30 mcg when administered subcutaneously (SC) to interferon-naïve participants with relapsing multiple sclerosis. The secondary objective of this study was to evaluate the safety and tolerability of ...
What is the current status of trial NCT00784836?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2008-10. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00784836?
The interventions under investigation include: BG9418 (interferon beta 1-a) (DRUG).
Who is sponsoring clinical trial NCT00784836?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.